NONOF News and Press, Novo-Nordisk A/S From 03/24/24

2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...

2024-03-21 13:35:23 ET More on Eli Lilly, Novo Nordisk, etc. Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Confer...

2024-03-20 13:09:31 ET More on Eli Lilly, Novo Nordisk, etc. Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Confer...

2024-03-18 10:02:54 ET Summary US providers for kidney dialysis and renal solutions, such as DaVita Inc. and Novo Nordisk, have seen significant gains in the past year. DaVita's decision to expand its renal care operations in Latin America, particularly in Brazil, Colombia, Ecuado...

2024-03-16 12:57:30 ET More on Madrigal Pharmaceuticals Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Ra...

2024-03-15 15:38:23 ET More on Eli Lilly Eli Lilly and Co (LLY) Cowen's 44th Annual Health Care Conference (Transcript) Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party UBS sees Lilly GLP-1/sl...

2024-03-15 08:19:55 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...

2024-03-14 15:45:17 ET More on Madrigal Pharmaceuticals Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade) Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's...

2024-03-14 07:20:30 ET More on WuXi AppTec, WuXi AppTec, etc. Potential U.S. Targeting Casts Shadow Over WuXi AppTec Family WuXi Biologics: Recent Share Price Recovery Isn't Sustainable Historical earnings data for WuXi AppTec Dividend scorecard for WuXi AppT...

2024-03-07 13:05:47 ET Summary Novo Nordisk had a strong performance in 2023, driven by a significant increase in obesity care sales and market leadership in the global diabetes market. The company plans to invest heavily in expanding its manufacturing base, with discussions of am...